A new €48 million investment by pharmaceutical company KELIX bio will be seeing the creation of a world-class manufacturing and distribution centre in Malta.
A governmental statement revealed that this instrument will be instrument in its cause to develop and commercialise affordable speciality generics for emerging economies.
Minister for Energy, Enterprise and Sustainable Development announced the investment, saying that it will create 100 quality jobs over the next three years. Dalli announced the investment during a visit at KELIX bio accompanied by Malta Enterprise Chief Executive Kurt Farrugia and KELIX chief executive Hocine Sidi-Said
The Minister explained how KELIX is an example of an investment which Malta wishes to attract. ‘Innovation and cost leadership are today being put into action. The investment being carried out by KELIX bio, with the support of the CDC, the Development Partners International and the European Bank for Reconstruction and Development, is an investment in citizens around the globe.’
KELIX bio is a specialty generic business which focuses on selected therapy areas and product forms of oncology, diabetes, anti-invectives and inhalers, injectables and biosimilars. They are exported to over 40 countries around the world and the company has acquired Italfarmaco SPA’s subsidiary Chemi Malta in Ħal Far.
It will be taking over its newly built world class, EU and US-FDA certified facility to augment its labour force with around 100 new professionals.
#MaltaDaily